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Summary/Conclusions: In our experience. AML-MRC occurs mainly In elderly 
patients and is associated with a poor prognosis. The age at diagnosis (and 
therefore, the probability of receiving intensive chemotherapy) seems to be a 
strong determinant of prognosis; also. CD56-positive cases exhibited a lower 
mortality rate than those negative. Further studies are needed to confirm these 
findings and new therapeutic strategies should be investigated to improve out­
come in this group of patients.
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Background: Anthracydine-induced cardiotoxicity is a complicated problem of 
treating patients with acute leukemia (AL). which can lead to the acute cardiac 
events development. Ischemic heart disease (IHD) is one of the cardiotoxicity 
risk factors, which requires monitoring of changes in myocardial bioelectric activity 
on the background of anthracydine low cumulative doses (CDs) In these patients. 
Aims: To assess the nature of electrocardiogram (ECG) changes on the back­
ground of anthracydine low CDs in patients with AL taking into account con­
comitant ischemic heart disease.
Methods: The study Involved 93 patients with newly diagnosed AL (acute lym­
phoblastic leukemia -  21 pts, acute myeloid leukemia -  72 pts), mean age 16- 
72 years, 48 (51.8%) men, 45 (48.2%) women, ECOG HI. Their polychemother­
apy (PCT) programs included anlhracydines. According to the presence of 
concomitant IHD patients were divided into two groups: I (n=57) -  AL patients 
without concomitant IHD; II (n=36) -  AL patients with concomitant IHD. The 
standard 12-lead ECG and dally ECG-monltoring were performed for patients 
of both groups in achieving the CD from 100 to 200 mg/m2 for doxorubidn, 
which amounted 179.5±24.11 mg/m2 and 172.1±23.15 mg/m2 in patients of 
groups I and II respectively. »
Results: The sinus tachycardia, repolarization processes violations and QRS 
complex voltage reduction were registered in 16 (28%) pts of group I according 
to the standard 12-lead ECG. In 29 (80.5%) pts of group II on the sinus tachy­
cardia background the following changes were revealed: right bundle branch 
block -  in 2 (5.6%) pts. left anterior fascicular block -  in 2 (5.6%) pts, first- 
degree atrioventricular block -  in 2 (5.6%) pts, supraventricular extrasystoles 
-  in 4 (11.1%) pts, lower voltage and repolarization processes reduction -  in 8 
(22.2%) pts The ST segment depression was registered in 13 (36.1%) pts, the 
Q-T interval prolongation -  in 6(16.6%) pts, T wave changes-in 6(16.7%) pts 
of group II. According to the daily ECG-monitoring in 28 (49%) pts of group I 
with minimal physical activity on the tachycardia background the episodes of 
solitary supraventricular extrasystoles were detected. In all 36 (100%) patients 
of group II the periods of tachycardia were recorded, that were accompanied 
by the increasing number of single supraventricular extrasystoles, episodes of 
paired and group supraventricular extrasystoles -  in 24 (66.6%) pts, single 
episodes of ventricular extrasystoles -  in 19 (52%) pts and increased number 
of clinically significant ST segment depression periods -  in 29 (80.5%) and Q- 
T prolongation -  in 14 (38.8%) patients.
Summary/Conclusions: Low CDs up to 100-200 mg/m2 for doxorubicin in AL 
patients without ischemic heart disease are accompanied by the cardiotoxic 
effects development in the form of arrhythmias: sinus tachycardia, supraven­
tricular extrasystoles. In case of concomitant ischemic heart disease presence 
the complex of myocardial bioelectric activity disorders develops, such as 
arrhythmias, conduction abnormalities and silent myocardial ischemia. With 
the purpose of early anthracycline-induced cardiotoxicity diagnosis in patients 
with AL receiving PCT it is necessary to conduct daily ECG-monitoring, which 
has greater sensitivity compared with standard 12-lead ECG.
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Background: Genetics is currently central to diagnosis, prognosis and measure 
of response to therapy (minimal residual disease, MRD) for patients with acute 
leukemia, myeloid or lymphoid. These tests are usually conducted on bone 
marrow aspirate by various techniques (karyotype, fluorescence in situ 
hybridization, reverse transcription polymerase chain reaction, or DNA sequenc­
ing). In case of a dry tap these most valuable information are often lost.
Alms: Since January 2014, we implemented a method for DNA and RNA 
extraction from bone marrow biopsy specimen in case of a dry tap at diagnosis 
or during follow up. Here we present the method, results and relevance of the 
analysis conducted so far.
Methods: Bone marrow biopsy is immediately sunken in either RNAIater (QIA- 
GEN, as for other products listed below) for transcript expression analysis such 
as acute myeloid leukemia (AML) recurrent genetic anomaly or MRD determi­
nation. In case DNA-based analysis is warranted, such as analysis of BCR 
rearrangements and NOTCH mutations, the biopsy specimen is put into phos­
phate buffer saline (PBS). Biopsy material is then manually crushed and solved 
in Qiazol for RNA and PBS for DNA. Manual extraction according to the 
phenol/chloroform is performed prior to RNA purification, quantification and 
reverse transcription according to manufacturer's Instruction. DNA purification 
and quantification is performed similarly. Analyses are performed according to 
established standards for bone marrow aspirates.
Results: We retrospectively identified 32 analysis from 20 patients with either 
acute lymphoid leukemia (ALL, n=6), acute myeloid leukemia (AML, n=12) or 
high risk myelodysplastic syndromes (MDS, n=2). Dry tap occurred either at 
diagnosis (n=11) or during follow up (n=21), regardless of diagnosis (lymphoid 
or myeloid neoplasia), blast count (median 5%. range: 1-95%) or marrow fibro­
sis (median 2. range 0-4). In seven samples, this technique allowed to identify 
a mutation in NMP1, with impact on diagnosis and prognosis, which is not 
amendable to other techniques (karyotype or FISH). Seventeen more samples 
allowed to quantify minimal residual disease (levels of WT1 or BCR-ABL tran­
scripts), which Is either not possible or less refined by alternative cytogenetic 
methods. Seven patients had more than one sample, which allowed correlation 
with and refinement of response assessment by histology. On 11 occasions 
(37.5%) the result of molecular analysis had a major impact on therapy (mostly 
distinction of Philadelphia positive vs negative ALL n=5, targeted therapy for 
FLT3-ITD transcript n=1, identification of relapse/refractory disease n=2, deci­
sion between autologous vs allogeneic transplantation for consolidation n=2). 
Summary/Conclusions: The method presented here is a readily accessible 
variant of the commonly used molecular diagnostic techniques. Its use can 
confirm, expand and usually refine the analysis available on the bone marrow 
biopsy specimen, and in one third of the cases, have a significant impact on 
therapy options.
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Background: Acute myeloid leukemia (AML) is disease of older adults with 
median age over 65 years. The effect of age and severe comorbidities are 
associated with high incidence of early death, low rate of complete remission 
(CR) and poor survival. Treatment options for elderly patients include: intensive 
chemotherapy, less-intensive regimens, best supportive care as well as enroll­
ment in clinical trials. Therapeutic decisions in older AML patients are highly 
challenging and need to be individualized since the outcome in this group 
remains still unsatisfactory.
Aims: The aim of the study was to compare results of different treatment strate­
gies in elderly patients with AML and to analyze overall survival in examined 
patients.
Methods: Patients. We describe a single center experience of 101 patients 
(41 females and 60 males) with diagnosis of AML. hospitalized in the Depart­
ment and Clinic of Hematology, Blood Neoplasms, and Bone Marrow Trans­
plantation, Wroclaw Medical University between 2007 and 2014. Median age 
was 70,6 years (range, 60-90 years). In 85 patients AML was diagnosed de 
novo, whereas 16 patients had secondary AML. Adverse, intermediate and 
favorable karyotype was found in 14,82 and 5 patients, respectively. All patients 
were enrolled into therapeutic procedures according to the age. karyotype, per­
formance status and comorbidity index. Fifty-five patients were treated with 
intensive chemotherapy regimen based on daunorubicin and cytarabine (DA, 
“3+5-7"), 22 patients obtained azacitidine (AZA), 14 patients were treated with 
low-dose cytarabine (LDAC), and only 10 patients received best supportive 
care (BSC). We estimated percent of CR, early mortality rate, leukemia free 
survival (LFS) and overall survival (OS).
Results: CR was achieved in 24 patients (44%) who received DA, and in 10 
patients (28%) with less-intensive therapy. LFS was comparable in both the*e 
groups (5 vs 4 months), but superior In patients who received DA. Eight-week 
early mortality rate was up to 15% after intensive induction therapy and 10% 
after AZA and LDAC regimens. Nevertheless, median OS in patients treated 
with DA was marginally superior (5 month) than in patients who received low 
Intensive treatment (4 month) and significantly longer than in patients with BSC 
(1 month).
Summary/Conclusions: The DA regimen remains still a best standard therapy 
in older AML patients with good performance status and low comorbidity index. 
Low-intensive treatment strategies (azacitidine, low-dose cytarabine) seem to 
be good therapeutic options for older patients with severe comorbidities.
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